CASIF — CASI Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $2.06m
- $38.79m
- $20.71m
Casi Pharma rises on FDA nod to test blood disorder drug in humans
Brief: CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug Application For CID-103 In Immune Thrombocytopenia
Brief: Casi Pharmaceuticals Files Mixed Shelf Of Upto $50 Mln - SEC Filing
Brief: CASI Pharmaceuticals Got Notice From Juventas Cell Therapy To Terminate Exclusive License Agreement
U.S. STOCKS ON THE MOVE-Nasdaq, Albemarle, Haemonetics
U.S. STOCKS ON THE MOVE-AeroVironment, Tesla, GitLab
U.S. STOCKS ON THE MOVE-Apogee Therapeutics ,Target, Enviva
Casi soars on positive early-stage data for blood cancer therapy
Brief: CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206
Brief: CASI Pharma Announces First Dosing Of FOLOTYN In China
Brief: Casi Pharmaceuticals Appointed Cnmc As Sole Distributor For Sale Of Pralatrexate
Brief: Casi Pharmaceuticals Announces Market Approval Of CNCTt19 By China NMPA
Brief: Mundipharma International, Mundipharma Medical Company, Acrotech Biopharma Enter Agreement To Transfer License Of FOLOTYN In China To CASI Pharmaceuticals
Brief: CASI Pharmaceuticals Acquires Global Intellectual Property Rights To Cleave Therapeutics' VCP/P97 Inhibitor CB-5339
Casi Pharma rises on lower Q1 loss
Brief: Casi Pharmaceuticals Announces First Quarter 2023 Financial Results
Casi Pharmaceuticals Inc Reports Results For The Quarter Ended In December: Earnings Summary
Brief: CASI Pharmaceuticals Announces Fourth Quarter And Full-Year 2022 Financial Results
Casi Pharmaceuticals Inc Expected To Post A Loss Of 37 Cents A Share: Earnings Preview